←Back to Expert Scholars
Translational Medicine / 转化医学KRAS Combination Therapy
Mark Awad
MD, PhD
🏢Dana-Farber Cancer Institute🌐USA
Chief, Thoracic Oncology
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Mark Awad leads thoracic oncology clinical research with a focus on KRAS mutant lung cancer and combination therapy with checkpoint inhibitors and SHP2 inhibitors. His work characterizes resistance to KRAS G12C inhibitors and informs combination trial design. He advances precision medicine for lung cancer.
Share:
🧪Research Fields 研究领域
lung cancer
KRAS
immunotherapy
targeted therapy
resistance
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Mark Awad 的研究动态
Follow Mark Awad's research updates
留下邮箱，当我们发布与 Mark Awad（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment